{"title":"Nitric Oxide Donor Metallodrug: Single-Inhaler Proposal for Rescue in Acute Allergic Asthma Crises.","authors":"Paula Priscila Correia Costa, Stefanie Bressan Waller, Hálef Herbet Ramos, Belarmino Eugênio Lopes Neto, Wesley Lyeverton Correia Ribeiro","doi":"10.3390/biology14030244","DOIUrl":null,"url":null,"abstract":"<p><p>Allergic asthma is characterized by chronic airway inflammation and recurrent bronchial hyperreactivity, highlighting the need for rapid therapeutic interventions during acute crises. This study aimed to assess the potential of a single-dose administration of the ruthenium nitrosyl complex <i>cis</i>-[Ru(bpy)<sub>2</sub>(2-MIM)(NO)](PG<sub>6</sub>)<sub>3</sub> (named as FOR811A) as a fast-acting treatment in a murine model of allergic asthma. Female Swiss mice were sensitized with ovalbumin for the induction of asthma and subjected to inhalation challenges. The experimental groups included controls and ovalbumin-sensitized mice receiving FOR811A (0.75 mg/kg) or saline (NaCl 0.9%), both by gavage. Lung tissues were collected for analyses of oxidative damage (nitrite/nitrate and GSH), inflammatory markers (myeloperoxidase, IL-1β, and IL-4), and histological assessment. The results showed that, while FOR811A did not significantly reduce oxidative damage or overall inflammation, it effectively decreased IL-4 levels, indicating a modulation of the Th2 immune response without affecting IL-1β levels (Th1 response). These findings suggest that a single-dose administration of FOR811A may provide a rapid therapeutic effect in allergic asthma crises by promoting smooth muscle relaxation and modulating immune responses. Further research is warranted to explore its clinical utility as a fast-acting rescue medication for acute asthma management.</p>","PeriodicalId":48624,"journal":{"name":"Biology-Basel","volume":"14 3","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940297/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biology-Basel","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3390/biology14030244","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Allergic asthma is characterized by chronic airway inflammation and recurrent bronchial hyperreactivity, highlighting the need for rapid therapeutic interventions during acute crises. This study aimed to assess the potential of a single-dose administration of the ruthenium nitrosyl complex cis-[Ru(bpy)2(2-MIM)(NO)](PG6)3 (named as FOR811A) as a fast-acting treatment in a murine model of allergic asthma. Female Swiss mice were sensitized with ovalbumin for the induction of asthma and subjected to inhalation challenges. The experimental groups included controls and ovalbumin-sensitized mice receiving FOR811A (0.75 mg/kg) or saline (NaCl 0.9%), both by gavage. Lung tissues were collected for analyses of oxidative damage (nitrite/nitrate and GSH), inflammatory markers (myeloperoxidase, IL-1β, and IL-4), and histological assessment. The results showed that, while FOR811A did not significantly reduce oxidative damage or overall inflammation, it effectively decreased IL-4 levels, indicating a modulation of the Th2 immune response without affecting IL-1β levels (Th1 response). These findings suggest that a single-dose administration of FOR811A may provide a rapid therapeutic effect in allergic asthma crises by promoting smooth muscle relaxation and modulating immune responses. Further research is warranted to explore its clinical utility as a fast-acting rescue medication for acute asthma management.
期刊介绍:
Biology (ISSN 2079-7737) is an international, peer-reviewed, quick-refereeing open access journal of Biological Science published by MDPI online. It publishes reviews, research papers and communications in all areas of biology and at the interface of related disciplines. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. Electronic files regarding the full details of the experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.